by Maria Zannes | Aug 12, 2020 | Press Releases
Precision Completes Development of CyPath® Lung and Starts CLIA Validation of Cancer Assay for Sale as a Laboratory Developed Test (LDT) FAQ: Answers to Questions about Cypath® Lung August 12, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech...
by Maria Zannes | Aug 11, 2020 | News
AUGUST 11, 2020 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal A local pathology practice has initiated a validation study of San Antonio-based bioAffinity Technologies’ CyPath Lung early...
by Maria Zannes | Aug 4, 2020 | Events, Press Releases
AUGUST 4, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced its presentation of a poster explaining the Company’s use of flow cytometry for diagnosis of lung disease including cancer at the International Society for...
by Maria Zannes | Jul 28, 2020 | Press Releases
JULY 28, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech company, today announced it has closed a non-brokered, secured convertible note (“Note”) financing for proceeds of $5,000,000.00 (the “Offering”). The proceeds...
by Maria Zannes | Jul 23, 2020 | Events
Dr. Lydia Bederka will present the poster “Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis” (Poster #P223) at the International Society for the Advancement of Cytometry conference, CYTO2020 on August 4-5, 2020. Cytometry is the quantitative...
